Sacubitril/valsartan versus in empagliflozin heart failure with preserved ejection fraction
نویسندگان
چکیده
Abstract Funding Acknowledgements Type of funding sources: None. Background Heart failure with preserved ejection fraction (HFpEF) is associated frequent hospitalizations and an increased risk death. Empagliflozin was recently reported to reduce the combined cardiovascular death or hospitalization for heart (HF) among patients HFpEF, whereas Sacubitril/Valsartan has shown only marginal significance benefits in these patients. We aimed compare value money treatments. Methods compared annualized Cost Needed Treat (CNT) prevent composite outcome HF Sacubitril/Valsartan. The CNT estimated by multiplying drug-specific annual cost Number Needed-to-Treat (aNNT) which calculated based on data from EMPEROR-Preserved PARAGON -HF trials Sacubitril-Valsartan, respectively. Costs were 2021 US prices. performed scenario analyses attenuate differences between studies’ populations. Subgroup across diabetes status. Results aNNT 61 (95% CI: 41-128) versus 53 (28-∞) Sacubitril-Valsartan PARAGON-HF, 4,797$ 6,298 $, corresponding CNTs therefore $292,620 196,679 - 614,023) $333,834 176,365 ∞) Sacubitril-Valsartan. In diabetic patients, $254,244 158,303 882,659) $308,639 132, 2740 non-diabetic $326,200 201,476 1,443,914) (170,066 Conclusion provides better than preventing HFpEF. This difference more pronounced diabetes.
منابع مشابه
Heart Failure With Preserved Ejection Fraction
The Journal of the American Osteopathic Association July 2015 | Vol 115 | No. 7 432 From Henry Ford Wyandotte Downriver Cardiology in Brownstown, Michigan (Dr Rogers); West Suburban Medical Center in Oak Park, Illinois (Dr Gundala); Oakwood Southshore Medical Center in Trenton, Michigan (Dr Ramos); and Elmhurst Memorial Hospital in Illinois (Dr Serajian). Drs Gundala and Ramos are in their thir...
متن کاملHeart Failure With Preserved Ejection Fraction
Symptomatic heart failure, despite preserved left ventricular (LV) ejection fraction, is a well-recognized phenomenon. This manifestation of diastolic dysfunction is associated with increased morbidity and mortality and can be attributed to a variety of pathogeneses, including diabetes mellitus, hypertension, infiltrative processes, and obesity. Unlike in systolic heart failure, where LV ejecti...
متن کاملHeart Failure with Preserved Ejection Fraction
1. Demonstrate the association between heart failure with preserved ejection fraction (HFpEF) and survival. 2. Given a patient with heart failure (HF), recognize HFpEF on the basis of clinical signs and symptoms, physical examination, echocardiography, and radiographic findings. 3. Classify patients at high risk of hospitalization and mortality through assessing risk factors, clinical presentat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Preventive Cardiology
سال: 2022
ISSN: ['2047-4881', '2047-4873']
DOI: https://doi.org/10.1093/eurjpc/zwac056.022